European office withdraws Nexium patent

Dec 21, 2006

The European Patent Office, answering a generic drug maker's challenge, withdrew a patent on Britain-based AstraZeneca PLC's heartburn treatment, Nexium.

AstraZeneca officials said they were disappointed with the patent office's decision, but had other patents and intellectual property measures that protected the drug in Europe, the Wall Street Journal said. The ruling involved the drug's chemical composition. The patent was due to expire in 2014.

The generic drug maker Ratiopharm International GmbH of Germany challenged the patent, which led to the EPO's decision. Ratiopharm has not indicated its plans regarding a generic form of Nexium.

Generic drug makers are challenging Nexium's patents in the United States.

AstraZeneca said Nexium's $4.6 billion in worldwide sales accounted for about a fifth of the company's third-quarter revenue.

Copyright 2006 by United Press International

Explore further: US appeals court upholds delay in Alzheimer's drug swap

Related Stories

Smart crystallization

Mar 02, 2015

A novel nucleating agent that builds on the concept of molecularly imprinted polymers (MIPs) could allow crystallographers access to proteins and other biological macromolecules that are usually reluctant ...

US Supreme Court weighs generic drug dispute

Oct 15, 2014

(AP)—The US Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.

India denies revoking Roche patent, says it lapsed

Aug 06, 2013

India on Monday denied revoking additional patents related to Roche Holding's breast cancer drug Herceptin, saying the Swiss giant failed to follow legal procedures so the applications lapsed.

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.